These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7603156)

  • 1. Cultural shift in Italy's drug policy.
    Garattini S
    Lancet; 1995 Jul; 346(8966):5-6. PubMed ID: 7603156
    [No Abstract]   [Full Text] [Related]  

  • 2. The cultural shift in Italy's pharmaceutical policy in 1994: a case history.
    Garattini S
    J Ambul Care Manage; 2004; 27(2):120-6. PubMed ID: 15069989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursable drug classes and ceilings in Italy: why not only one?
    Garattini L; Curto A; Padula A
    Eur J Health Econ; 2016 Nov; 17(8):923-926. PubMed ID: 27255742
    [No Abstract]   [Full Text] [Related]  

  • 4. Battle looms over regulatory classification of complex drugs.
    Hersher R
    Nat Med; 2012 Apr; 18(4):474-5. PubMed ID: 22481390
    [No Abstract]   [Full Text] [Related]  

  • 5. On the Policy of the Italian Government in the Discovery, Development, and Access to Medicines.
    Scavone C; Carnovale C; Ruggiero R; Radice S; Scatigna M; Racagni G; Mugelli A; Rossi F; Clementi E; Capuano A
    Clin Ther; 2018 Nov; 40(11):1931-1940. PubMed ID: 30458933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of gatt agreement on drug prices.
    Pillai AM
    J Indian Med Assoc; 1995 Mar; 93(3):113, 120. PubMed ID: 8522810
    [No Abstract]   [Full Text] [Related]  

  • 7. Differentiating drugs by harm potential: the rational versus the feasible.
    Kalant H
    Subst Use Misuse; 1999 Jan; 34(1):25-34. PubMed ID: 10052388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 9. ECJ 2009/5 A. Menarini and others, 2 April 2009 (joined cases C-352/07 to C-356/07, C-365/07 to C-367/07 and C-400/07).
    Bayens A; Goffin T;
    Eur J Health Law; 2009 Dec; 16(4):381-5. PubMed ID: 19927428
    [No Abstract]   [Full Text] [Related]  

  • 10. Is Australia's national medicines policy failing? The case of COX-2 inhibitors.
    Vitry A; Lexchin J; Mansfield PR
    Int J Health Serv; 2007; 37(4):735-44. PubMed ID: 18072318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. So much time for so little: Italy's pharmaceutical industry and doctors' information needs.
    Maestri E; Furlani G; Suzzi F; Campomori A; Formoso G; Magrini N
    BMJ; 2000 Jan; 320(7226):55-6. PubMed ID: 10617540
    [No Abstract]   [Full Text] [Related]  

  • 12. Everything you always wanted to know about drug cryptomarkets* (*but were afraid to ask).
    Barratt MJ; Aldridge J
    Int J Drug Policy; 2016 Sep; 35():1-6. PubMed ID: 27523571
    [No Abstract]   [Full Text] [Related]  

  • 13. The menace of substandard drugs.
    Roy J
    World Health Forum; 1994; 15(4):406-7. PubMed ID: 7999239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of China's national essential medicines policy.
    Guan X; Liang H; Xue Y; Shi L
    J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 16. [Generic drug: standards, organizational and economic aspects of the use of galenicals within the National Health Service].
    Marchetti M; Riccieri FM
    Farmaco Prat; 1982 Jul; 37(7):215-25. PubMed ID: 7128772
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply by authors.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2014 Jun; 116(2-3):236-7. PubMed ID: 24530141
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug rackets.
    Mani MK
    Natl Med J India; 2010; 23(4):242-3. PubMed ID: 21192523
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale drug therapy: reasons for failure and suggestions for its implementation.
    Mathur GP; Kushwaha KP; Mathur S
    Indian Pediatr; 1993 Jun; 30(6):815-8. PubMed ID: 7726879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.